Headache Inducing Effect of Levcromakalim in Migraine With Aura Patients
NCT ID: NCT04012047
Last Updated: 2020-03-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
17 participants
INTERVENTIONAL
2019-07-09
2019-12-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Migraine Inducing Effect of Levcromakalim in Patients With Migraine With Aura
NCT04905654
Headache Inducing Effect of Cromakalim in Migraine Patients
NCT03228355
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.
NCT05565001
Headache Inducing Effect of NN414 in Migraine Patients
NCT04744129
The Effects of Levcromakalim in Patients With Cluster Headache
NCT05093582
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Levcromakalim
Levcromakalim
To investigate the role of levcromakalim compared with placebo in migraine with aura patients
Saline
Saline
To investigate the role of levcromakalim compared with placebo in migraine with aura patients
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Levcromakalim
To investigate the role of levcromakalim compared with placebo in migraine with aura patients
Saline
To investigate the role of levcromakalim compared with placebo in migraine with aura patients
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18-60 years.
* 50-100 kg.
Exclusion Criteria
* Daily consumption of drugs of any kind other than oral contraceptives
* Pregnant or nursing women.
* Cardiovascular disease of any kind, including cerebrovascular diseases.
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Danish Headache Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohammad Al-Mahdi Al-Karagholi
MD, PhD student
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Messoud Ashina
Role: STUDY_DIRECTOR
Danish Headache Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Danish headache center
Glostrup Municipality, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Al-Karagholi MA, Ghanizada H, Nielsen CAW, Hougaard A, Ashina M. Opening of ATP sensitive potassium channels causes migraine attacks with aura. Brain. 2021 Sep 4;144(8):2322-2332. doi: 10.1093/brain/awab136.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Journal-nr.: H-19023571
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.